Launched in 2025, Africa's new medicines regulator is working to win the support of countries to meet its extensive agenda.

The devastation caused by COVID-19 brought pandemic prevention, preparedness, and response (PPPR) to the forefront of the global political agenda. But in many quarters, global attention has waned amid ...

The disparity in global childhood cancer survival is well known: survival probabilities exceed 80% in high-income countries, whereas they remain around 30% in low-income countries.1–3 But there are ...

The African Union, through the Africa Centres for Disease Control and Prevention (CDC), has operationalised strategies on non-communicable diseases (NCDs), injuries, and mental health to reverse the ...

For the first time in the history of both the National Aeronautics and Space Administration (NASA) and the International Space Station, a crew medical concern prompted an unprecedented evacuation, ...

Despite its enormous global burden, osteoarthritis has no licensed disease-modifying treatments, and available analgesics have moderate efficacy and substantial side-effects.1 The success of ...

My mom and I left Iran when I was 5 years old, just the two of us…there had been the revolution in 1979, so it was a combination of factors, wanting to get her PhD, but also wanting to get away from ...

Alberti, writer and Professor in Modern History at King's College London, UK, was 5 years into an ambitious research project ...

We thank Alberto Enrico Maraolo and colleagues for their careful reading of our Seminar1 on community-acquired pneumonia and for raising an important point: the expanding therapeutic armamentarium ...

The principle that medicines should not reach patients without strong safety guardrails forms the bedrock of the US Food and Drug Administration (FDA). The FDA shapes decisions about which medicines ...

Ophthalmology pioneered the clinical use of artificial intelligence (AI). Beyond automating routine tasks, including retinal ...

David Beran and colleagues argue that the GLP-1 receptor agonists might not have been appropriate for addition to the 2025 WHO Essential Medicines List (EML) for three reasons.e First, the authors ...